- Home
- PHVS
PHVS
Pharvaris N.V.
as of 07-17-2026 3:54pm EST
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
| Founded: | 2015 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.4B | IPO Year: | 2020 |
| Target Price: | $41.82 | AVG Volume (30 days): | 566.0K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $19.12 - $36.60 | Next Earning Date: | 05-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered PHVS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pharvaris N.V. (PHVS)
Chief Executive Officer
Avg Cost/Share
$34.97
Shares
2,292
Total Value
$80,154.45
Owned After
132,917
SEC Form 4
Chief Early Development
Avg Cost/Share
$35.48
Shares
58,575
Total Value
$2,078,527.39
Owned After
93,969
Avg Cost/Share
$35.49
Shares
30,712
Total Value
$1,090,048.73
Owned After
315,167
SEC Form 4
Chief Early Development
Avg Cost/Share
$35.07
Shares
17,597
Total Value
$616,924.75
Owned After
93,969
Avg Cost/Share
$35.08
Shares
9,288
Total Value
$325,696.97
Owned After
315,167
Chief Early Development
Avg Cost/Share
$35.12
Shares
4,600
Total Value
$161,560.28
Owned After
93,969
Chief Executive Officer
Avg Cost/Share
$31.25
Shares
2,291
Total Value
$71,173.04
Owned After
132,917
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Modig Berndt | PHVS | Chief Executive Officer | Jul 13, 2026 | Sell | $34.97 | 2,292 | $80,154.45 | 132,917 | |
| Lesage Anne | PHVS | Chief Early Development | Jun 30, 2026 | Sell | $35.48 | 58,575 | $2,078,527.39 | 93,969 | |
| Schikan Johannes Gerardus Christiaan Petrus | PHVS | Director | Jun 30, 2026 | Sell | $35.49 | 30,712 | $1,090,048.73 | 315,167 | |
| Lesage Anne | PHVS | Chief Early Development | Jun 29, 2026 | Sell | $35.07 | 17,597 | $616,924.75 | 93,969 | |
| Schikan Johannes Gerardus Christiaan Petrus | PHVS | Director | Jun 29, 2026 | Sell | $35.08 | 9,288 | $325,696.97 | 315,167 | |
| Lu Peng | PHVS | Chief Medical Officer | Jun 26, 2026 | Sell | $34.00 | 14,700 | $499,847.04 | 65,631 | |
| Lu Peng | PHVS | Chief Medical Officer | Jun 25, 2026 | Sell | $34.77 | 15,000 | $518,984.94 | 65,631 | |
| Lesage Anne | PHVS | Chief Early Development | Jun 25, 2026 | Sell | $35.12 | 4,600 | $161,560.28 | 93,969 | |
| Lu Peng | PHVS | Chief Medical Officer | Jun 18, 2026 | Sell | $34.00 | 300 | $10,200.00 | 65,631 | |
| Modig Berndt | PHVS | Chief Executive Officer | Jun 15, 2026 | Sell | $31.25 | 2,291 | $71,173.04 | 132,917 |
Compare PHVS vs Leading Stocks
See how PHVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.